Mohamed Elsafy։ Rethinking Hemostatic Management in Glanzmann Thrombasthenia with Sutacimig
Mohamed Elsafy, Drug Safety and Pharmacovigilance Lead Physician, Global Safety Strategy and Governance at ClinRM LLC, shared a post on LinkedIn:
”Sutacimig represents a novel and potentially transformative approach in Glanzmann thrombasthenia, shifting the paradigm from reactive bleeding management to true prophylaxis.
By leveraging a bispecific mechanism to localize and stabilize endogenous Factor VIIa at the platelet surface, this strategy directly addresses the underlying hemostatic defect. Early data showing meaningful reductions in bleeding burden are encouraging, particularly in a setting with no established preventive options.
If sustained in later-stage studies, this could redefine the standard of care in rare platelet disorders.”
Stay updated with Hemostasis Today.
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV
-
Jul 7, 2026, 22:52Harry Spoelstra: LongC0VID Still has Zero Proven Treatments
-
Jul 7, 2026, 22:39Satya K. Morar: Acute Portal Vein Thrombosis as an Exceptionally Rare Complication of Liver Biopsy in CVID
-
Jul 7, 2026, 22:23Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’
-
Jul 7, 2026, 20:59William Aird: An Unlucky Turn Into the Renal Artery
-
Jul 7, 2026, 20:58Chokri Ben Lamine: The Two-Hit Model of TRALI
-
Jul 7, 2026, 20:57New Issue of Blood Out Now – Blood Journals Portfolio
-
Jul 7, 2026, 20:56Priyadarshini Ramakrishnan: Schistocytes – The Most “Misleading Heroes” in a Peripheral Smear